Detalhe da pesquisa
1.
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Nature
; 597(7878): 732-737, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34526717
2.
Inhibition of nonsense-mediated decay rescues p53ß/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers.
J Biol Chem
; 297(5): 101163, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34481841
3.
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
J Thorac Oncol
; 19(1): 106-118, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37678511
4.
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes.
Cancer Cell
; 42(2): 225-237.e5, 2024 02 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38278149
5.
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy.
Clin Cancer Res
; 29(1): 30-39, 2023 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35969170
6.
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
Clin Cancer Res
; 29(7): 1292-1304, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36595561
7.
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
Cancer Cell
; 41(2): 340-355.e6, 2023 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36787696
8.
Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.
Cancers (Basel)
; 14(14)2022 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35884533
9.
Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado.
Mol Cancer Res
; 20(2): 280-292, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34654720
10.
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Cancer Cell
; 40(7): 754-767.e6, 2022 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35820397
11.
ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC.
Cancer Cell
; 39(9): 1178-1180, 2021 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34388379
12.
Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC.
J Thorac Oncol
; 16(12): 2051-2064, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34311109
13.
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
J Thorac Oncol
; 16(2): 205-215, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33096270
14.
Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.
J Thorac Oncol
; 16(3): 439-451, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33309987
15.
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
Cancer Prev Res (Phila)
; 14(3): 313-324, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33277316
16.
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology.
J Thorac Oncol
; 16(11): 1821-1839, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34274504
17.
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.
bioRxiv
; 2021 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32577652
18.
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
J Thorac Oncol
; 16(4): 583-600, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33388477
19.
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Clin Cancer Res
; 15(10): 3484-94, 2009 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19447865
20.
ß-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers.
J Neuroimmune Pharmacol
; 15(1): 27-36, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31828732